Treating Relapsed/Refractory Multiple Myeloma With Bispecific Therapy

home / case-based-roundtable-series / treating-relapsed-refractory-multiple-myeloma-with-bispecific-therapy

This roundtable series assesses later-line treatment of patientswith relapsed/refractory multiple myeloma, as discussed by key opinion leaders and participants at virtual live events.

Goals and Efficacy of the MajesTEC-1 Trial in Multiple Myeloma

Goals and Efficacy of the MajesTEC-1 Trial in Multiple Myeloma

Thomas G. Martin, MD
November 23rd 2022

Thomas G. Martin, MD, discusses the goals and efficacy outcomes of the phase 1/2 MajesTEC-1 trial of teclistamab-cqyv for patients with relapsed/refractory multiple myeloma.

Managing Infections During Bispecific Therapy for Multiple Myeloma

Managing Infections During Bispecific Therapy for Multiple Myeloma

Shaji Kumar, MD
December 23rd 2022

Shaji Kumar, MD, discusses the incidence and management of infections in patients receiving teclistamab-cqyv or other bispecific agents for relapsed/refractory multiple myeloma.

Bispecific T-Cell Engagers Improve Immune Response in Multiple Myeloma

Bispecific T-Cell Engagers Improve Immune Response in Multiple Myeloma

Thomas G. Martin, MD
March 3rd 2023

Thomas G. Martin, MD, discusses the mechanism of action of bispecific T-cell engagers including teclistamab-cqyv in patients with relapsed/refractory multiple myeloma.

BCMA Therapies Changing Treatment in Relapsed/Refractory Multiple Myeloma

BCMA Therapies Changing Treatment in Relapsed/Refractory Multiple Myeloma

Targeted Oncology Staff
March 16th 2023

During a Targeted Oncology™ Case-Based Roundtable™ event, Rafael Fonseca, MD, discusses how targeting patients with relapsed/refractory multiple myeloma with B-cell maturation antigens like teclistamab is changing the treatment landscape.

Teclistamab Provides a Superior Response for Patients with R/R Multiple Myeloma

Teclistamab Provides a Superior Response for Patients with R/R Multiple Myeloma

Targeted Oncology Staff
March 21st 2023

During a Targeted Oncology™ Case-Based Roundtable™ event, Rafael Fonseca, MD, discusses the efficacy and safety with teclistamab for patients with relapsed/refractory multiple myeloma.

Strategies for Patients with Relapsed/Refractory Multiple Myeloma

Strategies for Patients with Relapsed/Refractory Multiple Myeloma

Targeted Oncology Staff
April 21st 2023

In a live virtual event, Jens Hillengass discussed the available treatment strategies for patients with relapsed/refractory multiple myeloma. This is first of 2 articles based on this event.

MajesTEC-1 Results Show Efficacy for Teclistamab in Multiple Myeloma

MajesTEC-1 Results Show Efficacy for Teclistamab in Multiple Myeloma

Targeted Oncology Staff
May 9th 2023

In a live virtual event, Jens Hillengass discussed the results of the MajesTEC-1 study and how teclistamab is used to treat patients with relapsed/refractory multiple myeloma. This is the second article in a 2-article series on this case.